Literature DB >> 28366377

Treatment of cystoid macular edema after cataract surgery.

Laura H P Wielders1, Jan S A G Schouten2, Merel R Aberle2, Verena A Lambermont2, Frank J H M van den Biggelaar2, Bjorn Winkens2, Rob W P Simons2, Rudy M M A Nuijts2.   

Abstract

The purpose of this review was to determine the optimum pharmacologic treatment for cystoid macular edema (CME) after cataract surgery in nondiabetic and diabetic patients. The Cochrane Library, Medline, and Embase databases were searched, and all randomized controlled trials (RCTs) that compared at least 2 pharmacologic strategies for CME after cataract surgery were included. Studies were excluded if preoperative CME or other risk factors for developing CME postoperatively were present. Ten RCTs were included in the systematic review. Five trials included at least 30 participants. Three RCTs showed a greater visual acuity improvement in patients treated with topical nonsteroidal antiinflammatory drugs (NSAIDs) than with a placebo. Other studies comparing the efficacy of topical NSAIDs, topical corticosteroids, sub-Tenon corticosteroids, oral NSAIDs, and oral acetazolamide did not report significant differences between treatment groups. Therefore, large RCTs are needed to provide evidence-based recommendations for the optimum treatment of CME after cataract surgery.
Copyright © 2017 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2017        PMID: 28366377     DOI: 10.1016/j.jcrs.2016.06.041

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  8 in total

1.  Persistence of Inflammation After Uncomplicated Cataract Surgery: A 6-Month Laser Flare Photometry Analysis.

Authors:  Michele De Maria; Marco Coassin; Valentina Mastrofilippo; Luca Cimino; Danilo Iannetta; Luigi Fontana
Journal:  Adv Ther       Date:  2020-05-21       Impact factor: 3.845

Review 2.  Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives.

Authors:  Bora Yüksel; Ömer Karti; Tuncay Kusbeci
Journal:  Clin Ophthalmol       Date:  2017-12-11

3.  Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema.

Authors:  Arash Maleki; Hossein Aghaei; Stacey Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-07

4.  Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac.

Authors:  Sabyasachi Sengupta; Dhaivat Vasavada; Utsab Pan; Manavi Sindal
Journal:  Indian J Ophthalmol       Date:  2018-06       Impact factor: 1.848

5.  Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study.

Authors:  Alejandro Gonzalez-De la Rosa; Jose Navarro-Partida; Juan Carlos Altamirano-Vallejo; Ada Gabriela Hernandez-Gamez; Jesus Javier Garcia-Bañuelos; Juan Armendariz-Borunda; Arturo Santos
Journal:  J Ocul Pharmacol Ther       Date:  2019-01-07       Impact factor: 2.671

6.  Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects.

Authors:  Christian J F Bertens; Suryan L Dunker; Aylvin J A A Dias; Frank J H M van den Biggelaar; Rudy M M A Nuijts; Marlies Gijs
Journal:  Transl Vis Sci Technol       Date:  2020-12-18       Impact factor: 3.283

7.  Distinct macular thickness changes after femtosecond laser-assisted cataract surgery of age-related cataract and myopia with cataract.

Authors:  Yong Wang; Jun Du; Mei Yang; Yi Xu; Huaijin Guan; Jian Wu
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

8.  Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.

Authors:  Athanassios K Giarmoukakis; Styliani V Blazaki; Georgios C Bontzos; Argyro D Plaka; Konstantinos N Seliniotakis; Larissa D Ioannidi; Miltiadis K Tsilimbaris
Journal:  Ther Clin Risk Manag       Date:  2020-11-06       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.